Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis

Eye

Volumn 23, Issue 5, 2009, Pages 1192-1198

  Tappeiner, C ^a,d   Roesel, M ^a   Heinz, C ^a   Michels, H ^b   Ganser, G ^c   Heiligenhaus, A ^a  

^a ST FRANZISKUS HOSPITAL   (Germany)

^b German Center for Pediatric Rheumatology   (Germany)

^c Department of Pediatric Rheumatology ^*  (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Childhood; Cyclosporine A; Immunosuppression; Iridocyclitis; Juvenile idiopathic arthritis; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; IMMUNOSPORINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; UNCLASSIFIED DRUG;

ADHESION; ADOLESCENT; ANUS DISEASE; ARTICLE; CATARACT; CHILD; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLAUCOMA; GLIOSIS; HUMAN; HYPERMENORRHEA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR HYPOTENSION; JUVENILE RHEUMATOID ARTHRITIS; KERATOPATHY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; UVEITIS; VITREOUS OPACITY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; UVEITIS;

EID: 65949117022     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.174     Document Type: Article

References (21)

1. Mingels A, Hudde T, Heinz C, Heiligenhaus A. Vision-threatening complications in childhood uveitis. Ophthalmologe 2005; 102: 477-484.
2. Andersson Gare B. Juvenile arthritisFwho gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 1999; 17: 367-374.
3. Manners PJ, Bower C. World-wide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002; 29: 1520-1530.
4. Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006; 244: 281-290.
5. Heiligenhaus A, Niewerth M, Mingels A, Ganser G, Thon A, Pleyer U et al. Epidemiology of uveitis in juvenile idiopathic arthritis from a national paediatric rheumatologic and ophthalmologic database. Klin Monatsbl Augenheilkd 2005; 222: 993-1001.
6. Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 2002; 86: 51-56.
7. Paroli MP, Speranza S, Marino M, Pirraglia MP, Pivetti-Pezzi P. Prognosis of juvenile rheumatoid arthritis-associated uveitis. Eur J Ophthalmol 2003; 13: 616-621.
8. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998; 82: 737-742.
9. Kotaniemi K. Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporin A and methotrexate. Clin Exp Rheumatol 1998; 16: 469-471.
10. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 2001; 40: 907-913.
11. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326: 1654-1660.
12. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight threatening uveitis in children and adolescents. Ophthalmology 1998; 105: 2028-2034.
13. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005; 140: 509-516.
14. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton 2001. J Rheumatol 2004; 31: 390-392.
15. Brooks P, Hochberg M. Outcome measures and classification criteria for the rheumatic diseases. A compilation of data from OMERACT (Outcome Measures for Arthritis Clinical Trials), ILAR (International League of Associations for Rheumatology), regional leagues and other groups. Rheumatology (Oxford) 2001; 40: 896-906.
16. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006; 45: 982-989.
17. Towler HM, Cliffe AM, Whiting PH, Forrester JV. Low-dose cyclosporin A therapy in chronic posterior uveitis. Eye 1989; 3: 282-287.
18. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996; 103: 365-373; discussion 373-374.
19. Schlote T, Dannecker G, Thiel HJ, Zierhut M. Cyclosporin A in therapy of chronic uveitis in childhood. Ophthalmologe 1996; 93: 745-748.
20. Hoyer PF, Offner G, Oemar BS, Brodehl J, Ringe B, Pichlmayr R. Four years' experience with cyclosporin A in pediatric kidney transplantation. Acta Paediatr Scand 1990; 79: 622-629.
21. Tugwell P. International consensus recommendations on cyclosporin use in rheumatoid arthritis. Drugs 1995; 50: 48-56.